GlassScriptPhysician profile
David Iner Stevens
NPI 1124423561
$5,035.82
in general payments reported to CMS, 2019-2025
36 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,154 · 2022: $819 · 2023: $985 · 2024: $924 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $714.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $629.58 | 2021-2025 | |
| Lilly USA, LLC | $457.25 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.44 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $332.42 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $261.83 | 2022-2025 | Rexulti |
| Corcept Therapeutics | $187.02 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.43 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $159.94 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $145.90 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $139.08 | 2021-2024 | |
| Lundbeck LLC | $127.39 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $119.34 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $118.21 | 2021-2023 | |
| Abbott Laboratories | $113.54 | 2023-2025 | Freestyle Libre 3, Proclaim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $97.77 | 2021-2024 | |
| Amgen INC. | $77.27 | 2022-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $75.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.49 | 2021-2023 | Gardasil 9 |
| Janssen Pharmaceuticals, INC | $69.16 | 2021 | |
| Xeris Pharmaceuticals, INC. | $64.15 | 2021-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $63.48 | 2021 | |
| Stryker Corporation | $55.94 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.64 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $48.01 | 2021-2024 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $45.36 | 2025 | Inspire |
| Inari Medical, INC. | $41.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cranial Technologies, INC | $37.48 | 2024-2025 | Doc Band |
| Nestle Healthcare Nutrition INC. | $34.87 | 2021-2023 | |
| Exact Sciences Corporation | $31.61 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $30.02 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Phathom Pharmaceuticals, INC. | $27.46 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $24.06 | 2025 | Hetlioz, Fanapt |
| Avanir Pharmaceuticals, INC. | $23.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.83 | 2024 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $15.50 | 2023 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.